AZD4360

AZD4360 is an antibody-drug conjugate developed by AstraZeneca. Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). The sponsor states: AZD4360 is an antibody-drug conjugate targeting Claudin 18.2, being studied in advanced solid tumours including gastric, gastro-oesophageal junction, biliary tract and pancreatic cancers. ClinicalTrials.gov describes the intervention as: Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer, biliary tract cancer and pancreatic ductal adenocarcinoma. The largest, NCT06921928, plans to enrol 31 participants (actual) with primary completion expected 2027-03-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.